ANRO
Price
$22.19
Change
-$1.13 (-4.85%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
915.13M
20 days until earnings call
Intraday BUY SELL Signals
NRXS
Price
$7.72
Change
-$0.20 (-2.53%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
99.46M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANRO vs NRXS

ANRO vs NRXS Comparison Chart in %
View a ticker or compare two or three
VS
ANRO vs. NRXS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a StrongBuy and NRXS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ANRO with price predictions
Oct 22, 2026

ANRO sees its Stochastic Oscillator ascends from oversold territory

On October 20, 2026, the Stochastic Oscillator for ANRO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 25 instances where the indicator left the oversold zone. In 23 of the 25 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANRO's RSI Indicator exited the oversold zone, 11 of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for ANRO just turned positive on October 20, 2026. Looking at past instances where ANRO's MACD turned positive, the stock continued to rise in 16 of 17 cases over the following month. The odds of a continued upward trend are 90%.

Following a +11.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANRO advanced for three days, in 150 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANRO as a result. In 38 of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

ANRO moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ANRO crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for ANRO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.174) is normal, around the industry mean (2.973). P/E Ratio (-10.052) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ANRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NRXS with price predictions
Oct 21, 2026

NRXS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 06, 2026

NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 25 cases where NRXS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on NRXS as a result. In 60 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for NRXS just turned positive on October 16, 2026. Looking at past instances where NRXS's MACD turned positive, the stock continued to rise in 25 of 30 cases over the following month. The odds of a continued upward trend are 83%.

NRXS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NRXS crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +19.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 122 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for NRXS moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.775) is normal, around the industry mean (2.988). P/E Ratio (-10.421) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
ANRONRXS
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
70%
N/A
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ANRO: $23.32 vs. NRXS: $7.92)
Brand notoriety: ANRO and NRXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 110% vs. NRXS: 48%
Market capitalization -- ANRO: $915.13M vs. NRXS: $99.46M
ANRO [@Biotechnology] is valued at $915.13M. NRXS’s [@Biotechnology] market capitalization is $99.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 2 FA rating(s) are green while NRXS’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 2 green, 3 red.
  • NRXS’s FA Score: 0 green, 5 red.
According to our system of comparison, ANRO is a better buy in the long-term than NRXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 4 TA indicator(s) are bullish while NRXS’s TA Score has 6 bullish TA indicator(s).

  • ANRO’s TA Score: 4 bullish, 5 bearish.
  • NRXS’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NRXS is a better buy in the short-term than ANRO.

Price Growth

ANRO (@Biotechnology) experienced а +7.42% price change this week, while NRXS (@Biotechnology) price change was +21.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ANRO is expected to report earnings on Nov 11, 2026.

NRXS is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ANRO
Daily Signal:
Gain/Loss:
NRXS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ANRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with NERV. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
-4.80%
NERV - ANRO
50%
Loosely correlated
+0.42%
CELC - ANRO
41%
Loosely correlated
+6.51%
PRAX - ANRO
38%
Loosely correlated
+0.96%
IMTX - ANRO
37%
Loosely correlated
-1.95%
SPRB - ANRO
37%
Loosely correlated
+7.65%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLTK2.06N/A
N/A
Playtika Holding Corp
HAL33.19-0.80
-2.35%
Halliburton Company
SDOT7.37-0.18
-2.38%
Sadot Group Inc.
USAR9.63-0.60
-5.87%
USA Rare Earth Inc
AIAI2.05-0.26
-11.26%
AIAI Holdings Corporation
Interesting Articles